Evaluation of urolithin A efficacy in heart failure patients with reduced ejection fraction

Mashhad University of Medical Sciences0 个研究点目标入组 10 人开始时间: 待定最近更新: 2021年4月26日

适应症

试验速览

暂无简介。

•Between the ages 25 to 85 years
•Left ventricular ejection fraction equal or lower than 40%
•New York Heart Association functional class equal or greater than II
•Received standard treatment of heart failure (including Angiotensin-converting enzyme 2 inhibitors or Angiotensin II receptor inhibitors and beta blockers) for at least 2 weeks
•Signed informed consent

•History of myocardial infarction during the 8 past weeks
•History of any malignant disease
•Renal failure (eGFR lower than 20 ml/1.73 m2/min)
•hepatic disorder (aminotransferase > 2x upper limit of normal)
•Extensive heart surgery or angioplasty during the past 30 days
•Allergy and/or hypersensitivity to specific drugs or substances related to drug used in this clinical trial
•uncontrolled high blood pressure (Systolic blood pressure higher than 180 mmHg and diastolic blood pressure higher than 100 mmHg)

发起方